Omnicell, Inc. 10-Q Summary: Period Ended June 30, 2002
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2002, and the six-month period ended on the same date. Omnicell, Inc. provides integrated clinical infrastructure and workflow automation solutions, primarily pharmacy and supply systems, to healthcare facilities. The company operates primarily in North America, with over 99% of revenues generated in this region for the quarter.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2002 |
Six Months Ended June 30, 2002 |
|---|---|---|
| Total Revenues | $24,942 | $49,361 |
| Gross Profit | $14,900 | $29,952 |
| Gross Margin | 59.7% | 60.7% |
| Net Income | $1,778 | $3,428 |
| Diluted EPS | $0.08 | $0.15 |
| Cash and Equivalents | $14,146 | $14,146 (Balance Sheet) |
| Short-term Investments | $7,150 | $7,150 (Balance Sheet) |
| Total Current Liabilities | $45,164 | $45,164 (Balance Sheet) |
| Long-term Debt | $0 | $0 |
Liquidity: As of June 30, 2002, the company held approximately $21.3 million in cash, cash equivalents, and short-term investments. The company had no outstanding borrowings under its previous credit facility which expired on June 30, 2002.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 19.7% year-over-year for the quarter and 23.9% for the six-month period. Product revenues grew 14.4% (quarter) and 19.8% (six months), driven by an increase in installed systems. Service and other revenues grew significantly, up 62.8% for the quarter and 56.4% for the six months.
- Profitability: The company returned to profitability, reporting net income of $1.78 million for the quarter and $3.43 million for the six months, compared to net losses of $1.21 million and $3.06 million in the same periods of 2001.
- Operating Expenses: Research and development expenses decreased 26.0% for the quarter and 12.6% for the six months, largely due to the capitalization of software development costs. Selling, general, and administrative (SG&A) expenses increased slightly (4.0% for the quarter) due to higher occupancy and professional fees.
- Cash Flow: Net cash used in operating activities improved significantly to $2.2 million for the six months ended June 30, 2002, compared to $9.2 million used in the prior year period. This improvement was driven by net income and changes in working capital, specifically a reduction in accrued liabilities and an increase in deferred service revenue.
Guidance, Outlook, and Risks
Management Commentary: Management anticipates that service and other revenues will continue to grow due to the expanding installed base. R&D expenses are expected to increase modestly in absolute dollars for the remainder of 2002, while SG&A expenses are projected to increase by no more than 5% compared to the prior year.
Subsequent Events: On August 1, 2002, the company established a new $12.5 million credit facility (comprising a $7.5 million revolving and a $5.0 million non-revolving facility) to replace the expired line of credit.
Risks and Contingencies:
- Customer Concentration: One leasing company accounted for 43.2% of accounts receivable as of June 30, 2002.
- Installation Delays: Revenue recognition is dependent on installation. Delays in installations, particularly with U.S. military customers following the September 11 attacks, can defer revenue recognition.
- Competition: The market is highly competitive with larger rivals like Pyxis Corporation (Cardinal Health) and Automated Healthcare (McKessonHBOC).
- Legal Proceedings: A lawsuit filed by a customer regarding lease indemnification was settled in May 2002 with no material adverse effect on the company.
Key Facts for Investor Verification
- Deferred Gross Profit: Verify the trend in deferred gross profit ($19.4 million at June 30, 2002 vs. $24.8 million at Dec 31, 2001), which indicates that installations exceeded shipments in the first half of the year, potentially signaling a slowdown in new orders or a catch-up in installations.
- Accounts Receivable Concentration: Confirm the creditworthiness of the single leasing company representing 43.2% of receivables.
- Capitalization of R&D: Review the impact of capitalizing $1.1 million in software development costs on the reported R&D expense reduction and future amortization schedules.
- Credit Facility Terms: Review the covenants of the new $12.5 million credit facility established in August 2002, specifically regarding liquidity thresholds and dividend restrictions.
- Military Sales: Monitor the status of delayed installations and new orders from U.S. military hospitals, which previously accounted for a small but notable portion of shipments.